Results 11 to 20 of about 219,018 (388)

Large‐scale screening for factor V Leiden (G1691A), prothrombin (G20210A), and MTHFR (C677T) mutations in Greek population

Health Science Reports, 2022
Background and aims To provide a fair estimate of the prevalence of factor V Leiden (FVL) (G1691A), prothrombin (G20210A), and MTHFR (C677T) mutations in the Greek population.
Alkistis Raptopoulou, Vassiliki Michou, Niki Mourtzi, Efstathia G. Papageorgiou, Chrysa Voyiatzaki, Vassilis Tsilivakos, Apostolos Beloukas, Thaleia A. Bei   +7 more
doaj   +1 more source

Blood coagulation factors and platelet response to drug‐induced hepatitis and hepatosis in rats

Animal Models and Experimental Medicine, 2023
Background Knowing the variability of blood coagulation responses to liver damage of different origins can provide a key to curing liver tissues or to mitigating treatment side effects.
Daria Korolova, Viktoriya Gryshchenko, Tamara Chernyshenko, Oleh Platonov, Olha Hornytska, Volodymyr Chernyshenko, Pavlo Klymenko, Yevdokiia Reshetnik, Tetyana Platonova   +8 more
doaj   +1 more source

Discovery of Screening Biomarkers for Major Depressive Disorder in Remission by Proteomic Approach

Diagnostics, 2021
Major depressive disorder (MDD) is a common disorder involving depressive mood and decreased motivation. Due to its high heterogeneity, novel biomarkers are required to diagnose MDD.
Hyebin Choi, Sora Mun, Eun-Jeong Joo, Kyu Young Lee, Hee-Gyoo Kang, Jiyeong Lee   +5 more
doaj   +1 more source

Prolonged prothrombin time at admission predicts poor clinical outcome in COVID-19 patients

World Journal of Clinical Cases, 2020
BACKGROUND The prognostic value of coagulation disorder in coronavirus disease 2019 (COVID-19) patients should be demonstrated. AIM To investigate the abnormalities of coagulation parameters in the patients with COVID-19 and their prognostic values ...
Lang Wang, Wenbo He, Xiaomei Yu, Dalong Hu, Hong Jiang   +4 more
semanticscholar   +1 more source

Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome

Frontiers in Immunology, 2020
BackgroundCritically ill patients with coronavirus disease 2019 (COVID-19) have a profound hypercoagulable state and often develop coagulopathy which leads to organ failure and death. Because of a prolonged activated partial-thromboplastin time (aPTT), a
Maria Orietta Borghi, Maria Orietta Borghi, Asmaa Beltagy, Asmaa Beltagy, Emirena Garrafa, Emirena Garrafa, Daniele Curreli, Germana Cecchini, Caterina Bodio, Claudia Grossi, Simonetta Blengino, Angela Tincani, Franco Franceschini, Laura Andreoli, Maria Grazia Lazzaroni, Silvia Piantoni, Stefania Masneri, Francesca Crisafulli, Duilio Brugnoni, Maria Lorenza Muiesan, Massimo Salvetti, Gianfranco Parati, Erminio Torresani, Michael Mahler, Francesca Heilbron, Francesca Pregnolato, Martino Pengo, Francesco Tedesco, Nicola Pozzi, Pier Luigi Meroni   +29 more
doaj   +1 more source

Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery – a pilot randomised controlled trial (PROPHESY trial)

Anaesthesia, 2020
There is equipoise regarding the use of prothrombin complex concentrate vs. fresh frozen plasma in bleeding patients undergoing cardiac surgery. We performed a pilot randomised controlled trial to determine the recruitment rate for a large trial ...
L. Green, N. Roberts, J. Cooper, S. Agarwal, S. Brunskill, I. Chang, R. Gill, A. Johnston, A. Klein, S. Platton, A. Rossi, A. Sepehripour, S. Stanworth, V. Monk, B. O'Brien   +14 more
semanticscholar   +1 more source

Structure of Coagulation Factor II: Molecular Mechanism of Thrombin Generation and Development of Next-Generation Anticoagulants

Frontiers in Medicine, 2018
Coagulation factor II, or prothrombin, is a multi-domain glycoprotein that is essential for life and a key target of anticoagulant therapy. In plasma, prothrombin circulates in two forms at equilibrium, “closed” (~80%) and “open” (~20%), brokered by the ...
Mathivanan Chinnaraj, William Planer, Nicola Pozzi   +2 more
doaj   +1 more source

The Conversion of Bovine Abnormal Prothrombin into Prothrombin [PDF]

Thrombosis and Haemostasis, 1977
In order to characterize the enzyme system which converts abnormal prothrombin (PIVKA-II) in prothrombin we prepared liver cell-free extracts from normal healthy cows. The enzyme system devoid of either precursor or prothrombin was isolated by differential centrifugation and partly purified with the aid of column chromatography.The carboxylation of ...
H.C. Hemker, Berry A.M. Soute, Cees Vermeer   +2 more
openaire   +1 more source

Factor V G1691A (Leiden) is a major etiological factor in Egyptian Budd-Chiari syndrome patients

Turkish Journal of Hematology, 2011
OBJECTIVE: Budd-Chiari syndrome is a multifactorial disease in which several prothrombotic disorders may predispose patients to the development of thrombosis at this uncommon location (hepatic veins). The aim of this study was to determine the prevalence
Tawhida Y. Abdel Ghaffar, Solaf M. Elsayed, Mohamed A. Sakr, Ezzat S. Elsobky, Sara M. Abdelhakam, Said Yousuf, Yonca Eğin, Nejat Akar   +7 more
doaj   +3 more sources

Thrombophilic molecular markers in young patients (<40 years) with coronary artery disease

Indian Journal of Pathology and Microbiology, 2012
Background: There has been an alarming rise in the incidence of coronary artery disease (CAD) in India especially involving the age group of less than 45 years. In recent past, various studies focused on hemostatic aspects of CAD, but could not determine
Mingma Sherpa, Satendra Sharma, Rajnish Avasthi   +2 more
doaj   +1 more source